Unit
- Skin Barrier Dysfunction: The primary defect in AD involves a compromised epidermal barrier due to mutations in the
filaggringene, leading to increased transepidermal water loss and allergen penetration. This barrier disruption is a key driver of disease chronicity. - Immune Dysregulation: AD is characterized by a predominant
Th2immune response with elevated cytokinesIL-4,IL-13, andIL-31, which promote inflammation and intense pruritus. Understanding this pathway guides targeted therapies. - Role of
IL-31: This cytokine is particularly associated with itch signaling, making it a target for emerging treatments. Pruritus is often the most distressing symptom for patients. - Microbiome Alterations: Patients with AD show reduced microbial diversity on the skin, with overgrowth of
Staphylococcus aureus. This colonization can exacerbate inflammation and flare frequency. - Environmental Triggers: Factors such as allergens (dust mites, pollen), irritants (soaps, detergents), and climate changes (low humidity) can precipitate flares by further damaging the barrier.
- Genetic Predisposition: Family history is a strong risk factor, with multiple genes involved in barrier function and immune regulation contributing to susceptibility.
- Chronic Inflammation Cycle: The interplay between barrier defect and immune activation creates a self-perpetuating cycle: scratching damages the barrier, which increases inflammation, which worsens itch.
- Systemic Involvement: AD is not limited to the skin; systemic inflammation can increase risk for comorbidities like asthma, allergic rhinitis, and food allergies, known as the atopic march.
- Neurogenic Inflammation: Sensory nerve fibers in the skin release neuropeptides such as substance P and calcitonin gene related peptide upon activation by pruritus. These neuropeptides promote vasodilation, mast cell degranulation, and further recruitment of immune cells, amplifying inflammation and itch. This neural component is an emerging therapeutic target.
- Role of Th17 and Th22 Cells: In chronic AD lesions, there is increased activity of Th17 and Th22 cells in addition to Th2. These cells produce cytokines IL-17 and IL-22, which contribute to epidermal hyperplasia, dysregulation of keratinocyte differentiation, and sustained inflammation. Their presence explains the chronicity and lichenification seen in longstanding disease.
- Sleep Disturbance and Quality of Life: Severe pruritus often leads to nocturnal scratching and fragmented sleep, significantly impairing quality of life. Patients may experience fatigue, mood disorders, and reduced productivity. Addressing sleep disruption is an important component of comprehensive care and patient education.
- Biomarkers of Disease Activity: Serum biomarkers such as total IgE, eosinophil count, and thymus and activation regulated chemokine (TARC/CCL17) correlate with disease severity. Monitoring these levels can help guide treatment decisions and assess response to therapy, though they are not yet standard in routine clinical practice.
Scope of Practice
Role: Clinical Operations Coordinator in Dermatology
Within scope:
- Educating patients on skin barrier protection and trigger avoidance
- Coordinating allergy testing referrals based on provider orders
- Documenting family history and environmental exposures
- Monitoring patient-reported itch severity using validated scales
- Facilitating communication between dermatology and primary care
Outside scope:
- Diagnosing AD or interpreting skin biopsy results
- Prescribing topical corticosteroids or systemic therapies
- Performing patch testing or allergy skin tests
- Modifying treatment plans without provider authorization
- Providing independent medical advice on management
Quick Revision
- AD pathophysiology centers on skin barrier dysfunction and Th2-dominant immune response.
- Filaggrin mutations and S. aureus colonization are key contributing factors.
- Clinical coordinators support patient education and documentation within defined scope.
- Systemic inflammation links AD to other atopic conditions.